全球產前和新生兒基因檢測市場規模（按檢測類型、應用、地區、範圍和預測）

產前及新生兒基因檢測市場規模及預測

2024 年產前和新生兒基因檢測市場規模價值 60.2 億美元，預計到 2030 年將達到 151.3 億美元，預測期內（2026-2032 年）的複合年成長率為 13.46%。

推動全球產前和新生兒基因檢測市場的因素

技術發展：聚合酵素鏈鎖反應(PCR)、次世代定序(NGS) 和微陣列分析等基因檢測技術的進步使得檢測更加準確和徹底。

遺傳病患病率不斷上升：嬰兒和胎兒中遺傳疾病和染色體異常的發生率不斷上升，推動了對基因檢測的需求，以便早期診斷疾病並及時治療。

接受度和認知度不斷提升：推動市場擴張的因素之一是家長和醫療專業人士對產前和新生兒篩檢基因檢測益處的認知不斷提高。隨著人們對早期檢測和早期療育價值的認知不斷提高，基因檢測正變得越來越被廣泛接受。

政府支持和措施：支持性法律法規加上政府推動新生兒篩檢計畫和提供產前基因檢測機會的宣傳活動正在幫助市場擴大。

母親年齡成長：高齡產婦的新生兒較容易出現染色體異常。許多女性為了確定自身基因異常的風險而延遲生育，這增加了產前篩檢和檢測服務的需求。

技術可負擔性和可近性：隨著基因檢測技術越來越廣泛地被消費者和醫療保健提供者所使用，其可負擔性和可近性也不斷提高，有助於推動市場擴張。

需求：非侵入性檢測技術 隨著消費者青睞無細胞胎兒 DNA 檢測等非侵入性產前檢測 (NIPT) 技術，市場正在擴大。

個人化醫療的快速發展：個人化醫療運動推動了產前和嬰兒護理中基因檢測的使用，該運動強調根據個人基因組成進行有針對性的干涉。

技術融合與整合：將基因檢測與其他醫學診斷技術相結合，將使產前和新生兒篩檢計劃更加有效和高效，有助於擴大市場。

增加醫療保健支出：透過使更多人能夠享受基因檢測服務，一般醫療保健支出的增加和保險公司對這些服務的覆蓋範圍的擴大都將支持行業成長。

限制全球產前和新生兒基因檢測市場的因素

法規合規性：由於嚴格的法規和核准程序，新的測試技術和工藝可能難以採用。為了將產品推向市場，公司必須應對複雜的法規環境。

倫理問題：隱私、知情同意以及基於基因資訊的歧視可能性是基因檢測引發的倫理問題之一。有些人可能不願意接受檢測，因為他們擔心自己的基因資訊會被雇主、保險公司和其他機構取得。

成本：一些個人和醫療保健系統可能會發現基因檢測的費用過高，尤其是在資源匱乏和保障不足的地區。高昂的價格可能會阻礙市場擴張，並限制檢測的可及性。

認知度和教育程度低：許多患者和醫療保健專業人員可能並未充分了解基因檢測的益處和局限性，這可能導致現有檢測的普及率較低。需要進行宣傳活動，提高人們對產前和新生兒基因檢測的認知和理解。

技術限制：儘管基因檢測取得了進展，但其特異性、敏感性和準確性仍然有限，尤其是在識別罕見遺傳疾病和突變方面。我們需要技術進步，使基因檢測更具臨床實用性和可靠性。

解讀困難：確定基因檢測觀察的含義可能很困難，需要專門訓練。缺乏遺傳學專業知識可能會使醫療專業人員難以為患者及其家屬提供適當的諮詢，並難以解讀檢測結果。

文化與社會因素：人們對基因檢測的決定可能受到其文化觀點、社會態度和宗教觀念的影響。此外，與遺傳疾病相關的文化禁忌和恥辱感也可能影響人們對基因檢測的接受程度。

資料安全和隱私：人們可能出於對資料安全和隱私侵犯的擔憂，不願接受基因檢測。患者不僅擔心自身基因資訊的保密性，還擔心其被濫用或非法取得。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 產前和新生兒基因檢測市場（按檢測類型）

• 攜帶者篩檢
• 非侵入性產前檢測（NIPT）
• 染色體微陣列分析（CMA）
• 生化基因檢測

5. 產前和新生兒基因檢測市場（按應用）

• 唐氏症篩檢
• 囊腫纖維化篩檢
• 脊髓性肌肉萎縮症（SMA）篩檢

第6章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第7章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第8章 競爭態勢

• 主要企業
• 市場佔有率分析

第9章 公司簡介

• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche AG（Roche Diagnostics）
• Natera
• Quest Diagnostics
• Laboratory Corporation of America（LabCorp）
• Thermo Fisher Scientific
• Bio-Rad Laboratories

第10章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第11章 附錄

• 簡稱列表
• 來源和參考文獻

Prenatal And Newborn Genetic Testing Market Size And Forecast

Prenatal And Newborn Genetic Testing Market size was valued at 6.02 USD Billion in 2024 and is projected to reach 15.13 USD Billion by 2030, growing at a CAGR of 13.46% during the forecast period 2026-2032.

Global Prenatal And Newborn Genetic Testing Market Drivers

The market drivers for the Prenatal And Newborn Genetic Testing Market can be influenced by various factors. These may include:

Technological Developments: More precise and thorough testing is made possible by the ongoing developments in genetic testing technologies, including polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray analysis.

Growing Prevalence of Genetic Disorders: In order to diagnose illnesses early and enable prompt therapies, there is an increasing need for genetic testing due to the increased frequency of genetic disorders and chromosomal abnormalities among infants and foetuses.

Growing Acceptance and Awareness: One factor driving market expansion is the growing knowledge among parents and medical professionals of the advantages of genetic testing for prenatal and neonatal screening. Genetic testing is becoming more widely accepted as awareness of the value of early detection and intervention grows.

Government Support and Initiatives: Supportive laws and regulations, in conjunction with government campaigns to advance newborn screening programmes and provide access to prenatal genetic testing, are what propel the market's expansion.

Growing Maternal Age: Newborns that have older mothers are more likely to have chromosomal abnormalities. Prenatal screening and testing services are in greater demand as many women put off having children in order to determine their risk of genetic abnormalities.

Technological Affordability and Accessibility: As genetic testing technologies become more widely available to consumers and healthcare providers, their affordability and accessibility are growing, propelling market expansion.

Wanted: Non-Invasive Testing Techniques The market is growing because consumers prefer non-invasive prenatal testing (NIPT) techniques such cell-free foetal DNA testing because they are less risky and have higher accuracy than invasive procedures like amniocentesis and chorionic villus sampling (CVS).

Rapid Growth in Personalised Medicine: The use of genetic testing in prenatal and infant care is being driven by the trend towards personalised medicine, which emphasises targeted interventions based on individual genetic makeup.

Technological Convergence and Integration: By combining genetic testing with other medical diagnostic techniques and technologies, prenatal and neonatal screening programmes may be made more effective and efficient, which will propel the market's expansion.

Growing Healthcare Expenditure: By making genetic testing services more widely available to a greater audience, the general increase in healthcare spending along with the insurance companies' growing coverage of these services both support the growth of the industry.

Global Prenatal And Newborn Genetic Testing Market Restraints

Several factors can act as restraints or challenges for the Prenatal And Newborn Genetic Testing Market . These may include:

Regulatory Compliance: New testing techniques and technologies may find it difficult to gain traction due to onerous regulatory regulations and approval procedures. To get their products to market, businesses have to traverse complicated regulatory environments, which can be expensive and time-consuming.

Ethical Concerns: Privacy, informed consent, and the possibility of discrimination based on genetic information are among the ethical issues that genetic testing brings up. Some people might be reluctant to get tested because they are concerned about the potential uses of their genetic information by employers, insurance companies, or other organisations.

Cost: Some people or healthcare systems may find the expense of genetic testing to be prohibitive, especially in areas with little resources or insufficient insurance coverage. Expensive prices could prevent market expansion and restrict access to testing.

Low Awareness and Education: There may be a low use of the available tests since many patients and healthcare professionals may not completely comprehend the advantages and restrictions of genetic testing. Campaigns to raise awareness and improve comprehension of prenatal and neonatal genetic testing are required.

Technological Restrictions: Despite advancements in genetic testing, specificity, sensitivity, and accuracy are still limited, especially when it comes to identifying uncommon genetic illnesses or variations. For genetic tests to be more clinically useful and reliable, technological advancements are required.

Interpretation Difficulties: Determining the meaning of genetic test findings can be difficult and need specific training. Lack of genetics expertise may make it difficult for medical professionals to appropriately counsel patients and their families and interpret test results.

Cultural and Societal Factors: People's decisions on genetic testing may be influenced by their cultural views, societal attitudes, and religious perspectives. Testing uptake may be impacted by cultural taboos or stigmas in some cultures related to genetic diseases.

Data Security and Privacy: People may be discouraged from having genetic testing done due to worries about data security and privacy violations. Patients might be concerned about misuse or illegal access to their genetic information, as well as its confidentiality.

Global Prenatal And Newborn Genetic Testing Market Segmentation Analysis

The Global Prenatal And Newborn Genetic Testing Market is Segmented on the basis of Test Type, Application, And Geography.

Prenatal And Newborn Genetic Testing Market, By Test Type

• Carrier Screening: This type of test identifies individuals who carry a gene mutation for a genetic disorder. Carrier screening can be done before pregnancy, during pregnancy, or after a baby is born.
• Non-Invasive Prenatal Testing (NIPT): NIPT is a blood test that can screen for certain chromosomal abnormalities in a fetus. NIPT is done during pregnancy, usually between 10 and 14 weeks.
• Chromosomal Microarray Analysis (CMA): CMA is a test that can detect small deletions or duplications of chromosomes. CMA can be used to diagnose a variety of genetic disorders, including intellectual disability, developmental delays, and birth defects.
• Biochemical Genetic Testing: Biochemical genetic testing measures the levels of enzymes or other chemicals in the blood or other tissues. Biochemical genetic testing can be used to diagnose a variety of genetic disorders, including metabolic disorders.

Prenatal And Newborn Genetic Testing Market, By Application

• Down Syndrome Screening: Down syndrome is a genetic disorder that causes developmental delays and intellectual disabilities. Down syndrome screening is a group of tests that can help to identify a pregnancy at increased risk of having a baby with Down syndrome.
• Cystic Fibrosis Screening: Cystic fibrosis is a genetic disorder that affects the lungs, pancreas, and other organs. Cystic fibrosis screening is a test that can identify babies who are carriers of the cystic fibrosis gene.
• Spinal Muscular Atrophy (SMA) Screening: Spinal muscular atrophy (SMA) is a genetic disorder that affects the muscles. SMA sc

Prenatal And Newborn Genetic Testing Market, By Geography

• North America: Market conditions and demand in the United States, Canada, and Mexico.
• Europe: Analysis of the Prenatal And Newborn Genetic Testing Market in European countries.
• Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.
• Middle East and Africa: Examining market dynamics in the Middle East and African regions.
• Latin America: Covering market trends and developments in countries across Latin America.

Key Players

• The major players in the Prenatal And Newborn Genetic Testing Market are:
• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche AG
• Natera
• Quest Diagnostics
• Laboratory Corporation of America
• Thermo Fisher Scientific
• Bio-Rad Laboratories

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Prenatal And Newborn Genetic Testing Market, By Test Type

• Carrier Screening
• Non-invasive Prenatal Testing (NIPT)
• Chromosomal Microarray Analysis (CMA)
• Biochemical Genetic Testing

5. Prenatal And Newborn Genetic Testing Market, By Application

• Down Syndrome Screening
• Cystic Fibrosis Screening
• Spinal Muscular Atrophy (SMA) Screening

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche AG (Roche Diagnostics)
• Natera
• Quest Diagnostics
• Laboratory Corporation of America (LabCorp)
• Thermo Fisher Scientific
• Bio-Rad Laboratories

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References